Reuters·2025-11-04 06:03Core Insights - Novo Nordisk's new CEO is under significant investor scrutiny as the company undergoes a board shakeup and engages in a bidding war with U.S. competitor Pfizer [1] Company Developments - The leadership transition at Novo Nordisk is expected to impact its strategic direction and investor confidence [1] - The company is actively pursuing a competitive strategy against Pfizer, indicating a heightened focus on market positioning and growth opportunities [1] Industry Context - The ongoing bidding war with Pfizer highlights the competitive landscape in the pharmaceutical industry, particularly in the obesity treatment market where Wegovy is a key product [1] - Investor attention is likely to increase as companies in the sector navigate mergers, acquisitions, and strategic partnerships [1]